Infographic
The epNEC Biomarker Journey: Where Could DLL3 Fit?
09/03/2026
This infographic maps the extrapulmonary neuroendocrine carcinoma (epNEC) biomarker journey from accurate diagnosis and classification through tissue stewardship, delta-like ligand 3 (DLL3) assessment, treatment planning, and clinical trial evaluation. The infographic emphasizes that DLL3 is a complementary therapeutic—not diagnostic—biomarker, requires assay-specific immunohistochemistry interpretation, and places pathologists at the center of tissue management, biomarker implementation, and multidisciplinary care.
© 2026 HMP Global. All Rights Reserved.
